Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders
NCT ID: NCT06661252
Last Updated: 2025-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
250 participants
OBSERVATIONAL
2025-01-08
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Novel Inflammatory Markers in Different Phenotypes of Severe Asthma
NCT04888910
Development and Validation of a Sputum Biomarker mRNA Panel for the Diagnostic Work-up of Asthma 1.
NCT01224938
Assessment of Oral and Nasal Breathing With Sensors Analyzing Algorithm
NCT05869071
C-Reactive Protein as a Predictor for Airway Hyper-Responsiveness
NCT01002144
Respiratory Pathogens of Patients With Asthma and COPD Exacerbations
NCT02866357
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Controls
Healthy volunteers.
ABEL microsampler device
The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
COPD sufferers
Previously diagnosed COPD sufferers.
ABEL microsampler device
The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
Asthma sufferers
Previously diagnosed asthma sufferers of various subtypes.
ABEL microsampler device
The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
Allergic rhinitis sufferers
Previously diagnosed seasonal or perennial allergic rhinitis sufferers.
ABEL microsampler device
The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
Chronic sinusitis sufferers
Previously diagnosed chronic sinusitis sufferers with/without nasal polyps.
ABEL microsampler device
The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABEL microsampler device
The ABEL microsampler device will be used to collect nasal fluid samples for biomarker analysis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or older
* The participant must be able to comprehend and sign an approved Informed Consent Form and other applicable study documents.
* Healthy volunteers:
* No significant sinonasal/pulmonary symptoms or prior diagnoses of sinonasal/pulmonary conditions as determined by pre-enrolment questionnaires.
* Case goup:
* Participants must be previously diagnosed with rhinitis, chronic sinusitis, asthma, or COPD by a medical professional.
Exclusion Criteria
* Volunteers who are actively pregnant
* Prior history of adverse reaction or contraindicated to diagnostic testing including fingerprick blood sampling, pulmonary testing, nasal swab/sampling.
* Any other conditions limiting the volunteer's ability to complete study requirements in the judgement of the investigator/clinician
* Any nasal anatomical issue or finding which may limit the safe insertion of the ABEL collection device, as determined by investigator/clinician
* History of nasal surgery or trauma within the last 3 months
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Diag-Nose Medical Pty Ltd
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diag-Nose Medical
Notting Hill, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DNM_002_V240930
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.